TAFI Antibodies

Santa Cruz Biotechnology features a diverse variety of TAFI monoclonal antibodies for research focused on understanding Thrombin Activatable Fibrinolysis Inhibitor (TAFI) in various biological processes. TAFI Antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). TAFI plays a crucial role in the regulation of fibrinolysis, the process by which blood clots are dissolved. By inhibiting the conversion of plasminogen to plasmin, TAFI helps maintain hemostasis and prevent excessive bleeding. Understanding TAFI function is essential for elucidating its involvement in thrombotic disorders and potential therapeutic targets. Researchers can investigate TAFI expression patterns across different tissue types and cellular locations. Advanced studies of TAFI can reveal new insights into blood clotting mechanisms and vascular diseases. Exploring TAFI's regulatory pathways may lead to breakthroughs in treating blood disorders. Santa Cruz Biotechnology monoclonal antibodies support researchers worldwide in advancing our understanding of cardiovascular health and disease mechanisms.